INTS - Intensity Therapeutics, Inc. So'nggi... | Finranks

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study Cash and cash equivalents of $9.5 million as of June 30, 2026 Increased business development activities Conference call begins at 8:00 a.m. Eastern time today SHELTON, Conn.

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate update SHELTON, Conn., Aug. 4, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on August 11, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study Cash and cash equivalents of $9.5 million as of June 30, 2026 Increased business development activities Conference call begins at 8:00 a.m. Eastern time today SHELTON, Conn.